PTO/SB/08a (01-10) Approved for use through 07/31/2012 OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE io a collection of information unless it contains a valid OMB control number

| | Application Number | | 10586930 | |
|---|---------------------------|------|--------------------|--|
| | Filing Date | | 2008-09-02 | |
| NFORMATION DISCLOSURE | First Named Inventor VASE | | ELLA, Mauro Alcide | |
| STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99) | Art Unit | | 2422 | |
| Not for submission under 57 Of K 1.33) | Examiner Name | LEE, | Michael | |
| | Attorney Docket Number | | PU040017 | |

| | | | | U.S. | PATENTS | Remove |
|----------------------|------------|-----------------------|---------------------------|---------------------|---|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | | | | | |
| If you wisl | h to add | additional U.S. Pater | t citatio | n information pl | ease click the Add button. | Add |
| | | | U.S.P | ATENT APPLI | CATION PUBLICATIONS | Remove |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | | | | | |

If you wish to add additional U.S. Published Application citation information please click the Add button. Remove

FOREIGN PATENT DOCUMENTS

| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² i | Kind Code ⁴ | Publication | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | TS |
|----------------------|------------|---|--------------------------------|---------------------------|-------------|---|---|----|
| | 1 | 2003-0071075 | KR | | 2003-09-03 | LGI CO., LTD. | | × |

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

| | NON-PATENT LITERATURE DOCUMENTS | Remove | |
|---------|---|--------------------------------|---|
| 07. | Include name of the author (in CAPITAL LETTERS), title of the article (when a | ppropriate), title of the item | Г |

(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), Initials* No publisher, city and/or country where published.

| 1 | |
|---|--|
| | |

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

18ex Kint Code of USPTO Petert Documents at Invest/ISPTO.GOL/ or MPEP 901.04. 2 Enter office that issued the document, by the Involvator occurred, and a code of the Ispace peter peter of the peter of the peter of the Peter or Investment peter of the pe

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 10586930 |
|----------------------|------|-------------------|
| Filing Date | | 2008-09-02 |
| First Named Inventor | VASE | LLA, Mauro Alcide |
| Art Unit | | 2422 |
| Examiner Name | LEE, | Michael |
| Attorney Docket Numb | er | PU040017 |

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign papel patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

| _ | | | |
|------------|----------------|---------------------|------------|
| Signature | /Reitseng Lin/ | Date (YYYY-MM-DD) | 2012-01-19 |
| Name/Print | Reitseng Lin | Registration Number | 42804 |

This collection of information is required by 3T CRR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR.

1.14. This collection is estimated to take if hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenski Office, V.S. operatment of Comments of Office, V.S. Agrandin, V.S. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, V.A. 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursyant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.